| scholarly article | Q13442814 |
| P50 | author | Michelle R Staudt | Q64539062 |
| Dirk Dittmer | Q71109132 | ||
| Sang-Hoon Sin | Q79326292 | ||
| P2093 | author name string | David Henry | |
| Ling Wang | |||
| Dhavalkumar D Patel | |||
| Farnaz D Fakhari | |||
| William J Harrington | |||
| Debasmita Roy | |||
| Blossom A Damania | |||
| P2860 | cites work | Human interleukin-6 is in vivo an autocrine growth factor for human herpesvirus-8-infected malignant B lymphocytes | Q40913931 |
| Constitutive cytokine production by primary effusion (body cavity-based) lymphoma-derived cell lines | Q40958887 | ||
| Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma | Q40972068 | ||
| Establishment and characterization of a primary effusion (body cavity-based) lymphoma cell line (BC-3) harboring kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus. | Q41164451 | ||
| The natural history and molecular heterogeneity of HIV-associated primary malignant lymphomatous effusions | Q41193978 | ||
| Real-time quantitative PCR analysis of viral transcription. | Q42639044 | ||
| Expression of p53 and human herpesvirus-8 (HHV-8)-encoded latency-associated nuclear antigen with inhibition of apoptosis in HHV-8-associated malignancies | Q42665921 | ||
| Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. | Q42814766 | ||
| Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition | Q43643471 | ||
| Viral IL-6-induced cell proliferation and immune evasion of interferon activity | Q44218062 | ||
| Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. | Q44260426 | ||
| Detection of human herpesvirus-8 DNA in kidney allografts prior to the development of Kaposi's sarcoma | Q44309430 | ||
| Prevalence, incidence and correlates of HHV-8/KSHV infection and Kaposi's sarcoma in renal and liver transplant recipients. | Q44448784 | ||
| Involvement of interleukin-10 (IL-10) and viral IL-6 in the spontaneous growth of Kaposi's sarcoma herpesvirus-associated infected primary effusion lymphoma cells | Q44761629 | ||
| mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways | Q44905183 | ||
| Immunosuppression, timing of human herpesvirus 8 infection, and risk of Kaposi's sarcoma among human immunodeficiency virus type 1-infected persons and transplant recipients | Q45739846 | ||
| Human herpes virus-8 and other risk factors for Kaposi's sarcoma in kidney transplant recipients. Groupe Cooperatif de Transplantation d' Ile de France (GCIF). | Q45749285 | ||
| Mechanisms of growth control of Kaposi's sarcoma-associated herpes virus-associated primary effusion lymphoma cells. | Q45757235 | ||
| Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts. | Q52008432 | ||
| Immortalization of primary endothelial cells by the K1 protein of Kaposi's sarcoma-associated herpesvirus. | Q53347753 | ||
| Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma–associated herpesvirus | Q56794246 | ||
| Posttransplantation Plasmacytic Proliferations Related to Kaposi's Sarcoma–Associated Herpesvirus | Q56999785 | ||
| Primary-Effusion Lymphoma and Kaposi's Sarcoma in a Cardiac-Transplant Recipient | Q60178452 | ||
| Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells | Q71563744 | ||
| Transcription profile of Kaposi's sarcoma-associated herpesvirus in primary Kaposi's sarcoma lesions as determined by real-time PCR arrays | Q73344152 | ||
| Relationship of HHV8 replication and Kaposi's sarcoma after solid organ transplantation | Q77415508 | ||
| Transmission of human herpesvirus 8 infection from renal-transplant donors to recipients | Q77509015 | ||
| Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex | Q24295120 | ||
| Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive | Q24306328 | ||
| Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. | Q27824772 | ||
| Post-transplant Kaposi sarcoma originates from the seeding of donor-derived progenitors | Q28190673 | ||
| Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma | Q28242984 | ||
| The tumor microenvironment controls primary effusion lymphoma growth in vivo | Q28272290 | ||
| Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease | Q29619158 | ||
| A cluster of latently expressed genes in Kaposi's sarcoma-associated herpesvirus | Q33784966 | ||
| p53 inhibition by the LANA protein of KSHV protects against cell death | Q33885642 | ||
| Spectrum of Kaposi's sarcoma-associated herpesvirus, or human herpesvirus 8, diseases | Q33906970 | ||
| An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice | Q33943166 | ||
| 4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin | Q34114303 | ||
| Charting latency transcripts in Kaposi's sarcoma-associated herpesvirus by whole-genome real-time quantitative PCR | Q34340317 | ||
| Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas | Q34536060 | ||
| Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. | Q34548882 | ||
| Sirolimus for Kaposi's sarcoma in renal-transplant recipients | Q34556363 | ||
| A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. | Q34585873 | ||
| Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay | Q34661407 | ||
| Human herpesvirus 8-encoded vGPCR activates nuclear factor of activated T cells and collaborates with human immunodeficiency virus type 1 Tat. | Q34976938 | ||
| Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma | Q35131811 | ||
| Will mTOR inhibitors make it as cancer drugs? | Q35604822 | ||
| Oncogenic gamma-herpesviruses: comparison of viral proteins involved in tumorigenesis | Q35841060 | ||
| Kaposi's sarcoma-associated herpesvirus-infected primary effusion lymphoma has a plasma cell gene expression profile | Q35918316 | ||
| Restraining PI3K: mTOR signalling goes back to the membrane. | Q36011048 | ||
| Kaposi's sarcoma in the era of HAART-an update on mechanisms, diagnostics and treatment. | Q36117364 | ||
| The Akt-mTOR tango and its relevance to cancer | Q36260264 | ||
| Human herpesvirus-8/Kaposi's sarcoma-associated herpesvirus is a new transmissible virus that infects B cells | Q36366617 | ||
| Human interferon-gamma-inducible protein 10 (IP-10) inhibits constitutive signaling of Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor | Q36401443 | ||
| Akt plays a central role in sarcomagenesis induced by Kaposi's sarcoma herpesvirus-encoded G protein-coupled receptor | Q37415110 | ||
| Identification of human herpesvirus 8-specific cytotoxic T-cell responses. | Q39594967 | ||
| Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells | Q39877852 | ||
| The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor as a therapeutic target for the treatment of Kaposi's sarcoma. | Q40333151 | ||
| Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum. | Q40377835 | ||
| Inhibition of phosphatidylinositol 3'-kinase/AKT signaling promotes apoptosis of primary effusion lymphoma cells. | Q40433643 | ||
| The K1 protein of Kaposi's sarcoma-associated herpesvirus activates the Akt signaling pathway | Q40594961 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cell biology | Q7141 |
| sirolimus | Q32089 | ||
| primary effusion lymphoma | Q3832899 | ||
| P304 | page(s) | 2165-2173 | |
| P577 | publication date | 2006-11-02 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling | |
| P478 | volume | 109 |
| Q35382266 | A Kaposi's sarcoma-associated herpesvirus-encoded ortholog of microRNA miR-155 induces human splenic B-cell expansion in NOD/LtSz-scid IL2Rγnull mice |
| Q42624833 | A unique herpesviral transcriptional program in KSHV-infected lymphatic endothelial cells leads to mTORC1 activation and rapamycin sensitivity |
| Q37102331 | A viral kinase mimics S6 kinase to enhance cell proliferation |
| Q38073761 | AKTivation of PI3K/AKT/mTOR signaling pathway by KSHV. |
| Q33419826 | Activation of host translational control pathways by a viral developmental switch |
| Q42592331 | Activation of mTORC1 signaling pathway in AIDS-related lymphomas |
| Q64102452 | Arachidonic Acid Derived Lipid Mediators Influence Kaposi's Sarcoma-Associated Herpesvirus Infection and Pathogenesis |
| Q46701461 | Bortezomib (PS-341) in patients with human herpesvirus 8-associated primary effusion lymphoma |
| Q92828080 | C19ORF66 Broadly Escapes Virus-Induced Endonuclease Cleavage and Restricts Kaposi's Sarcoma-Associated Herpesvirus |
| Q35046691 | Combination of arsenic and interferon-α inhibits expression of KSHV latent transcripts and synergistically improves survival of mice with primary effusion lymphomas |
| Q36882284 | Contribution of viral and cellular cytokines to Kaposi's sarcoma-associated herpesvirus pathogenesis |
| Q34303583 | Contribution of viral mimics of cellular genes to KSHV infection and disease. |
| Q30418735 | Cooperative roles for emmprin and LYVE-1 in the regulation of chemoresistance for primary effusion lymphoma |
| Q64277776 | Curbing Lipids: Impacts ON Cancer and Viral Infection |
| Q38264454 | Current status of treatment for primary effusion lymphoma |
| Q38097263 | Cyclooxygenase-2-prostaglandin E2-eicosanoid receptor inflammatory axis: a key player in Kaposi's sarcoma-associated herpes virus associated malignancies |
| Q35743839 | Cytokine homologs of human gammaherpesviruses |
| Q64128205 | Development of an ORF45-Derived Peptide To Inhibit the Sustained RSK Activation and Lytic Replication of Kaposi's Sarcoma-Associated Herpesvirus |
| Q33896731 | Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas |
| Q36122839 | Dysregulation of fatty acid synthesis and glycolysis in non-Hodgkin lymphoma |
| Q34549450 | EBV and HIV-Related Lymphoma |
| Q37906986 | Evi1 forms a bridge between the epigenetic machinery and signaling pathways. |
| Q40258774 | Evidence for a Mesothelial Origin of Body Cavity Effusion Lymphomas |
| Q35453657 | Extracellular Hsp90 serves as a co-factor for MAPK activation and latent viral gene expression during de novo infection by KSHV. |
| Q61800540 | Extracellular vesicles from Kaposi Sarcoma-associated herpesvirus lymphoma induce long-term endothelial cell reprogramming |
| Q42832950 | FLIP-mediated autophagy regulation in cell death control |
| Q39631647 | Fucoxanthin and its deacetylated product, fucoxanthinol, induce apoptosis of primary effusion lymphomas |
| Q42637800 | Functional signatures identified in B-cell non-Hodgkin lymphoma profiles. |
| Q58778363 | Gene essentiality landscape and druggable oncogenic dependencies in herpesviral primary effusion lymphoma |
| Q34597442 | HIV/AIDS: epidemiology, pathophysiology, and treatment of Kaposi sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease |
| Q40590036 | Herpesvirus Respiratory Infections in Immunocompromised Patients: Epidemiology, Management, and Outcomes. |
| Q47138406 | Herpesvirus and Autophagy: "All Right, Everybody Be Cool, This Is a Robbery!" |
| Q28485399 | Hsp90 inhibitors are efficacious against Kaposi Sarcoma by enhancing the degradation of the essential viral gene LANA, of the viral co-receptor EphA2 as well as other client proteins |
| Q37888397 | Human herpesvirus 8-associated neoplasms: the roles of viral replication and antiviral treatment. |
| Q46763759 | Human herpesvirus-8 (HHV-8)-associated primary effusion lymphoma in two renal transplant recipients receiving rapamycin |
| Q41876102 | Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning |
| Q33923893 | Inhibition of the phosphatidylinositol 3-kinase-Akt pathway enhances gamma-2 herpesvirus lytic replication and facilitates reactivation from latency |
| Q90244925 | Interleukin-1 Receptor Associated Kinase (IRAK) signaling in Kaposi Sarcoma-associated herpesvirus (KSHV) induced Primary Effusion Lymphoma |
| Q39046910 | KSHV LANA and EBV LMP1 induce the expression of UCH-L1 following viral transformation |
| Q33761091 | KSHV and the pathogenesis of Kaposi sarcoma: listening to human biology and medicine |
| Q26742030 | KSHV-Mediated Angiogenesis in Tumor Progression |
| Q94012444 | Kaposi sarcoma |
| Q38114627 | Kaposi sarcoma associated herpesvirus pathogenesis (KSHV)--an update |
| Q38962850 | Kaposi sarcoma herpesvirus-associated cancers and related diseases |
| Q35127940 | Kaposi sarcoma-associated herpesvirus (KSHV): molecular biology and oncogenesis |
| Q56345322 | Kaposi sarcoma-associated herpesvirus latency locus renders B cells hyperresponsive to secondary infections |
| Q38943741 | Kaposi sarcoma-associated herpesvirus: immunobiology, oncogenesis, and therapy |
| Q90319829 | Kaposi's Sarcoma-Associated Herpesvirus (KSHV)-Associated Disease in the AIDS Patient: An Update |
| Q36524036 | Kaposi's Sarcoma-Associated Herpesvirus Latency Locus Compensates for Interleukin-6 in Initial B Cell Activation |
| Q92376588 | Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication Interferes with mTORC1 Regulation of Autophagy and Viral Protein Synthesis |
| Q42141115 | Kaposi's sarcoma-associated herpesvirus confers a survival advantage to endothelial cells |
| Q92185487 | Kinome profiling of non-Hodgkin lymphoma identifies Tyro3 as a therapeutic target in primary effusion lymphoma |
| Q37004096 | Liposomal daunorubicin as treatment for Kaposi's sarcoma |
| Q34640985 | Liver transplantation in HCV/HIV positive patients |
| Q37074284 | Mammalian target of rapamycin (mTOR) pathway signalling in lymphomas |
| Q92327692 | Mechanistic Insights into Chemoresistance Mediated by Oncogenic Viruses in Lymphomas |
| Q92238951 | Modulation of Angiogenic Processes by the Human Gammaherpesviruses, Epstein-Barr Virus and Kaposi's Sarcoma-Associated Herpesvirus |
| Q37068487 | Modulation of B-cell exosome proteins by gamma herpesvirus infection |
| Q39173806 | Modulation of oncogenic signaling networks by Kaposi's sarcoma-associated herpesvirus |
| Q38111130 | Modulation of the autophagy pathway by human tumor viruses |
| Q90319823 | Molecular Biology of KSHV in Relation to HIV/AIDS-Associated Oncogenesis |
| Q40144368 | Multi-targeted therapy of everolimus in Kaposi's sarcoma associated herpes virus infected primary effusion lymphoma |
| Q60628572 | Non-Hodgkin Lymphoma Metabolism |
| Q33508240 | Non-human primate model of Kaposi's sarcoma-associated herpesvirus infection |
| Q40070266 | Nuclease escape elements protect messenger RNA against cleavage by multiple viral endonucleases |
| Q40203795 | PS-341 or a combination of arsenic trioxide and interferon-alpha inhibit growth and induce caspase-dependent apoptosis in KSHV/HHV-8-infected primary effusion lymphoma cells |
| Q35235757 | Phosphatase and tensin homolog on chromosome 10 is phosphorylated in primary effusion lymphoma and Kaposi's sarcoma |
| Q30423529 | Phosphorylation of eukaryotic translation initiation factor 4B (EIF4B) by open reading frame 45/p90 ribosomal S6 kinase (ORF45/RSK) signaling axis facilitates protein translation during Kaposi sarcoma-associated herpesvirus (KSHV) lytic replication |
| Q38194434 | Primary effusion lymphoma in an elderly patient effectively treated by lenalidomide: case report and review of literature |
| Q55518093 | Primary effusion lymphoma: current perspectives. |
| Q36238539 | RNA Sequencing Reveals that Kaposi Sarcoma-Associated Herpesvirus Infection Mimics Hypoxia Gene Expression Signature. |
| Q34160579 | Rapalogs in viral cancers |
| Q28476740 | Rapamycin blocks production of KSHV/HHV8: insights into the anti-tumor activity of an immunosuppressant drug |
| Q35827892 | Rapamycin with antiretroviral therapy in AIDS-associated Kaposi sarcoma: an AIDS Malignancy Consortium study |
| Q35664106 | Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas. |
| Q38449592 | Recent advances in the study of Kaposi's sarcoma-associated herpesvirus replication and pathogenesis |
| Q26751238 | Recent advances in understanding Kaposi's sarcoma-associated herpesvirus |
| Q35192690 | Ribosomal protein S6 interacts with the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus |
| Q38150876 | Signaling pathways in lymphoma: pathogenesis and therapeutic targets |
| Q38772976 | Synthesis of Rapamycin Derivatives Containing the Triazole Moiety Used as Potential mTOR-Targeted Anticancer Agents |
| Q30414412 | Systematic analysis of a xenograft mice model for KSHV+ primary effusion lymphoma (PEL) |
| Q34845533 | Systemically circulating viral and tumor-derived microRNAs in KSHV-associated malignancies. |
| Q33793543 | Targeted therapy for Kaposi's sarcoma and Kaposi's sarcoma-associated herpesvirus. |
| Q21135231 | Targeting KSHV/HHV-8 latency with COX-2 selective inhibitor nimesulide: a potential chemotherapeutic modality for primary effusion lymphoma |
| Q64258880 | Targeting mTOR with MLN0128 Overcomes Rapamycin and Chemoresistant Primary Effusion Lymphoma |
| Q28081199 | Targeting of prosurvival pathways as therapeutic approaches against primary effusion lymphomas: past, present, and Future |
| Q30408885 | Targeting sphingosine kinase induces apoptosis and tumor regression for KSHV-associated primary effusion lymphoma. |
| Q34131954 | Targeting the mammalian target of Rapamycin to inhibit VEGF and cytokines for the treatment of primary effusion lymphoma |
| Q30409463 | Targeting xCT, a cystine-glutamate transporter induces apoptosis and tumor regression for KSHV/HIV-associated lymphoma |
| Q41909242 | The Role of mTOR Inhibitors for the Treatment of B-Cell Lymphomas |
| Q34522360 | The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma |
| Q35582498 | The role of PI3K/Akt in human herpesvirus infection: From the bench to the bedside |
| Q37367299 | Treatment for Kaposi sarcoma herpesvirus: great challenges with promising accomplishments |
| Q35895560 | Treatment of Kaposi sarcoma-associated herpesvirus-associated cancers |
| Q35172518 | Tumor suppressor genes FHIT and WWOX are deleted in primary effusion lymphoma (PEL) cell lines. |
| Q34168712 | Update on KSHV epidemiology, Kaposi Sarcoma pathogenesis, and treatment of Kaposi Sarcoma |
| Q36205470 | Virus-Mediated Alterations in miRNA Factors and Degradation of Viral miRNAs by MCPIP1. |
| Q37791919 | When autophagy meets viruses: a double-edged sword with functions in defense and offense |
| Q36278593 | mTOR activity in AIDS-related diffuse large B-cell lymphoma |
| Q36745445 | mTOR inhibitors block Kaposi sarcoma growth by inhibiting essential autocrine growth factors and tumor angiogenesis |
Search more.